Shen Ethan PhDDirector · CEO
4
Filed Sep 16, 2026Period of report Sep 14, 20260001213900-26-100506
| Transaction | Security | Shares | Price | ValueValue (shares × price) | Held after | Ownership |
|---|---|---|---|---|---|---|
PurchaseSep 14, 2026 | Ordinary SharesF1 | 12,700 | $3.85 | $48.90K | 11,258,331 | Direct |
Filing footnotes · 2
- F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.67 to $3.97, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Ordinary Shares purchased at each separate price within the range set forth above.
- F2The reported shares are held by YD Biopharma Holding Limited, which is wholly owned by E820N Assets Ltd. (BVI), which is wholly owned by The E820N Trust (the "Trust"). Dr. Shen is the settlor, protector and sole beneficiary of the Trust, and is the beneficial owner of such shares.